CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
CVI.00100-07v1
14/12/1644    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yuan, F. F.
Right arrow Articles by Sullivan, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yuan, F. F.
Right arrow Articles by Sullivan, J. S.
Clinical and Vaccine Immunology, December 2007, p. 1644-1645, Vol. 14, No. 12
1071-412X/07/$08.00+0     doi:10.1128/CVI.00100-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

High Prevalence of the CD14-159CC Genotype in Patients Infected with Severe Acute Respiratory Syndrome-Associated Coronavirus{triangledown}

Fang F. Yuan,1,3* Ingrid Boehm,1 Paul K. S. Chan,2,5 Katherine Marks,1 Julian W. Tang,2 David S. C. Hui,4,5 Joseph J. Y. Sung,4,5 Wayne B. Dyer,1,3 Andrew F. Geczy,3 and John S. Sullivan1,3

Australian Red Cross Blood Service-Endeavour, Sydney, NSW 2000, Australia,1 Department of Microbiology, The Chinese University of Hong Kong, Hong Kong,2 Research Unit of Transfusion Medicine and Immunogenetics, Faculty of Medicine, University of Sydney, Sydney, Australia,3 Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong,4 Stanley Ho Centre for Emerging Infectious Diseases, School of Public Health, The Chinese University of Hong Kong, Hong Kong5

Received 28 February 2007/ Returned for modification 15 May 2007/ Accepted 27 September 2007

To investigate whether genetic factors of innate immunity might influence susceptibility and/or progression in individuals infected with SARS, we evaluated the CD14 gene polymorphism in 198 Hong Kong blood donors and 152 Hong Kong severe acute respiratory syndrome (SARS) patients who were previously genotyped for Fc{gamma}RIIA polymorphisms. The prevalence of the CD14-159CC polymorphism was significantly higher in the patients with severe SARS than in the those with mild SARS or controls (31% versus 15% [mild SARS] or 20% [controls]; mild SARS: P = 0.029; odds ratio, 2.74; 95% confidence interval, 1.15 to 6.57; controls, P = 0.04; odds ratio, 2.41; 95% confidence interval, 1.05 to 5.54), and both CD14-159CC and Fc{gamma}RIIA-RR131 are risk genotypes for severe SARS-CoV infection.

* Corresponding author. Mailing address: Cell Biology Laboratory, ARCBS-Endeavour, 153 Clarence Street, Sydney, NSW 2000, Australia. Phone: 61 2 9229 4523. Fax: 61 2 9229 4521. E-mail: fyuan{at}arcbs.redcross.org.au

{triangledown} Published ahead of print on 3 October 2007.

Clinical and Vaccine Immunology, December 2007, p. 1644-1645, Vol. 14, No. 12
1071-412X/07/$08.00+0     doi:10.1128/CVI.00100-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.





Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 2007 by the American Society for Microbiology. All rights reserved.